Engagement of ICAM-3 provides a costimulatory signal for human immunodeficiency virus type 1 replication in both activated and quiescent CD4+ T lymphocytes: Implications for virus pathogenesis

Journal of Virology

Volumn 78, Issue 12, 2004, Pages 6692-6697

  Barat, Corinne ^a   Gervais, Philippe ^a   Tremblay, Michel J ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CIS ACTING ELEMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 3; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CONTROLLED STUDY; ENHANCER REGION; EXPRESSION VECTOR; GEL MOBILITY SHIFT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKOCYTE ADHERENCE; LONG TERMINAL REPEAT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 2642540744     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.12.6692-6697.2004     Document Type: Article

References (56)

1. Acevedo, A., M. A. del Pozo, A. G. Arroyo, P. Sanchez-Mateos, R. Gonzalez-Amaro, and F. Sanchez-Madrid. 1993. Distribution of ICAM-3-bearing cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. Am. J. Pathol. 143:774-783.
2. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman transfected cells with an infectious molecular clone. J. Virol. 59:284-291.
3. Barat, C., and M. J. Tremblay. 2002. Engagement of CD43 enhances human immunodeficiency virus type 1 transcriptional activity and virus production that is induced upon TCR/CD3 stimulation. J. Biol. Chem. 277:28714-28724.
4. Barbeau, B., G. A. Robichaud, J.-F. Fortin, and M. J. Tremblay. 2001. Negative regulation of the NFAT1 factor by CD45: implication in HIV-1 LTR activation. J. Immunol. 167:2700-2713.
5. Berney, S. M., T. Schaan, J. S. Alexander, G. Peterman, P. A. Hoffman, R. E. Wolf, H. van der Heyde, and T. P. Atkinson. 1999. ICAM-3 (CD50) cross-linking augments signaling in CD3-activated peripheral human T lymphocytes. J. Leukoc. Biol. 65:867-874.
6. Bleijs, D. A., M. E. Binnerts, S. J. van Vliet, C. G. Figdor, and Y. van Kooyk. 2000. Low-affinity LFA-1/ICAM-3 interactions augment LFA-1/ICAM-1-mediated T cell adhesion and signaling by redistribution of LFA-1. J. Cell Sci. 113:391-400.
7. Bonyhadi, M. L., L. Rabin, S. Salili, D. A. Brown, J. Kosek, J. McCune, and H. Kaneshima. 1993. HIV induces thymus depletion in vivo. Nature 363:728-732.
8. + T-cell depletion in human lymphoid tissue, a major site of replication n vivo. J. Virol. 76:1004-1014.
9. Bukrinsky, M. I., T. L. Stanwick, M. P. Dempsey, and M. Stevenson. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254:423-427.
10. Campanero, M. R., M. A. del Pozo, A. G. Arroyo, P. Sanchez-Mateos, T. Hernandez-Caselles, A. Craig, R. Pulido, and F. Sanchez-Madrid. 1993. ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway. J. Cell Biol. 123:1007-1016.
11. Canonne-Hergaux, F., D. Aunis, and E. Schaeffer. 1995. Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J. Virol. 69:6634-6642.
12. Cefai, D., P. Debre, M. Kaczorek, T. Idziorek, B. Autran, and G. Bismuth. 1990. Human immunodeficiency virus-1 glycoprotein gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway. J. Clin. Investig. 86:2117-2124.
13. Cefai, D., M. Ferrer, N. Serpente, T. Idziorek, A. Dautry-Varsat, P. Debre, and G. Mismuth. 1992. Internalization of HIV glycoprotein gp120 is associated with down-modulation of membrane CD4 and p561ck together with impairment of T cell activation. J. Immunol. 149:285-294.
14. Chang, L. J., V. Urlacher, T. Iwakuma, Y. Cui, and J. Zucali. 1999. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6:715-728.
15. Chun, T. W., R. T. Davey, Jr., M. Ostrowski, J. Shawn Justement, D. Engel, J. I. Mullins, and A. S. Fauci. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.
16. + T cells using a combination of cytokines. J. Exp. Med. 188:83-91.
17. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.
18. Cid, M. C., J. Esparza, M. Juan, A. Miralles, J. Ordi, R. Vilella, A. Urbano-Marquez, A. Gaya, J. Vives, and J. Yague. 1994. Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in beta 1 and beta 2 integrin function. Eur. J. Immunol. 24:1377-1382,
19. Copeland, K. F. T., P. J. Hendrikx, A. G. M. Haaksma, S. Fiering, R. Van Lier, J. Goudsmit, and J. L. Heeney. 1995. Comparison of the response to T-cell activation by integrated HIV-1 and HTLV-1 LTR-lacZ vectors. Virology 209:633-636.
20. Cordell, J. L., K. Pulford, H. Turley, M. Jones, K. Micklem, I. A. Doussis, X. Tyler, K. Mayne, K. C. Gatter, and D. Y. Mason. 1994. Cellular distribution of human leucocyte adhesion molecule ICAM-3. J. Clin. Pathol. 47:143-147.
21. Cron, R. Q., S. R. Bartz, A. Clausell, S. J. Bort, S. J. Klebanoff, and D. B. Lewis. 2000. NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells. Clin. Immunol. 94:179-191.
22. del Pozo, M. A., M. R. Campanero, P. Sanchez-Mateos, A. G. Arroyo, R. Pulido, C. Munoz, T. Hernandez-Caselles, P. Aparicio, and F. Sanchez-Madrid. 1994. Role of ICAM-3 in intercellular adhesion and activation of T lymphocytes. Cell Adhes. Commun. 2:211-218.
23. 2 treatment leads to potent activation of human T-cell leukemia virus type 1. J. Virol. 77:11170-11179.
24. Fawcett, J., C. L. Holness, L. A. Needham, H. Turley, K. C. Gatter, D. Y. Mason, and D. L. Simmons. 1992. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 360:481-484.
25. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, C. G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
26. Geijtenbeek, T. B., G. C. van Duijnhoven, S. J. van Vliet, E. Krieger, G. Vriend, C. G. Figdor, and Y. van Kooyk. 2002. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J. Biol. Chem. 277:11314-11320.
27. Giffin, M. J., J. C. Stroud, D. L. Bates, K. D. von Koenig, J. Hardin, and L. Chen. 2003. Structure of NFAT1 bound as a dimer to the HIV-1 LTR kappa B element. Nat. Struct. Biol. 10:800-806.
28. Henderson, A. J., X. Zou, and K. L. Calame. 1995. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J. Virol. 69:5337-5344.
29. Hernandez-Caselles, T., G. Rubio, M. R. Campanero, M. A. del Pozo, M. Muro, F. Sanchez-Madrid, and P. Aparicio. 1993. ICAM-3, the third LFA-1 counterreceptor, is a co-stimulatory molecule for both resting and activated T lymphocytes. Eur. J. Immunol. 23:2799-2806.
30. Kinoshita, S., B. K. Chen, H. Kaneshima, and G. P. Nolan. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95:595-604.
31. Kinoshita, S., L. Su, M. Amano, L. A. Timmerman, H. Kaneshima, and G. P. Nolan. 1997. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235-244.
32. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72:3161-3168.
33. Kulkosky, J., G. Nunnari, M. Otero, S. Calarota, G. Dornadula, H. Zhang, A. Malin, J. Sullivan, Y. Xu, J. DeSimone, T. Babinchak, J. Stern, W. Cavert, A. Haase, and R. J. Pomerantz. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
34. Kulkosky, J., and R. J. Pomerantz. 2002. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin. Infect. Dis. 35:1520-1526.
35. Martinez-Caceres, E., G. Ruggiero, H. Spits, M. Juan, J. Barcelo, J. Vives, J. Martorell, and O. Vinas. 1996. Stimulation through CD50 (ICAM-3) induces both activation and programmed cell death of human thymocytes. Tissue Antigens 48:626-635.
36. Moriuchi, H., M. Moriuchi, and A. S. Fauci. 1999. Induction of HIV-1 replication by allogeneic stimulation. J. Immunol. 162:7543-7548.
37. Nabel, G. J., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713.
38. Pierson, T., J. McArthur, and R. F. Siliciano. 2000. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18:665-708.
39. Pierson, T. C., Y. Zhou, T. L. Kieffer, C. T. Ruff, C. Buck, and R. F. Siliciano. 2002. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76:8518-8531.
40. Pohlmann, S., E. J. Soilleux, F. Baribaud, G. J. Leslie, L. S. Morris, J. Trowsdale, B. Lee, N. Coleman, and R. W. Dorms. 2001. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc. Natl. Acad. Sci. USA 98:2670-2675.
41. Rabbi, M. F., M. Saifuddin, D. S. Gu, M. F. Kagnoff, and K. A. Roebuck. 1997. U5 region of the human immunodeficiency virus type 1 long terminal repeat contains TRE-like cAMP-responsive elements that bind both AP-1 and CREB/ATF proteins. Virology 233:235-245.
42. Sadhu, C., B. Lipsky, H. P. Erickson, J. Hayflick, K. O. Dick, W. M. Gallatin, and D. E. Staunton. 1994. LFA-1 binding site in ICAM-3 contains a conserved motif and non-contiguous amino acids. Cell Adhes. Commun. 2:429-440.
43. Schwartz, O., J.-L. Virelizier, L. Montagnier, and U. Hazan. 1990. A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity. Gene 88:197-205.
44. Sommerfelt, M. A., and B. Asjo. 1995. Intercellular adhesion molecule 3, a candidate human immunodeficiency virus type 1 co-receptor on lymphoid and monocytoid cells. J. Gen. Virol. 76:1345-1352.
45. Su, L., H. Kaneshima, M. Bonyhadi, S. Salimi, D. Kraft, L. Rabin, and J. M. McCune. 1995. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity 2:25-36.
46. Sun, S.-C., J. Elwood, and W. C. Greene. 1996. Both amino- and carboxy-terminal sequences within IκBα regulate its inducible degradation. Mol. Cell. Biol. 16:1058-1065.
47. Tong-Starkesen, S. E., P. A. Luciw, and B. M. Peterlin. 1989. Signaling through T lymphocyte surface proteins, TCR/CD3 and CD28, activates the HIV-1 long terminal repeat. J. Immunol. 142:702-707.
48. Unutmaz, D., V. N. KewalRamani, S. Marmon, and D. R. Littman. 1999. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189:1735-1746.
49. Vallejo, A. N., E. Bryl, K. Klarskov, S. Naylor, C. M. Weyand, and J. J. Goronzy. 2002. Molecular basis for the loss of CD28 expression in senescent T cells. J. Biol. Chem. 277:46940-46949.
50. Vazeux, R., P. A. Hogman, J. K. Tomita, E. S. Dickinson, P. L. Jasman, T. St. John, and W. M. Gallatin. 1992. Cloning and characterization of a new intercellular adhesion molecule ICAM-R. Nature 360:485-488.
51. Watts, T. H., and M. A. DeBenedette. 1999. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11:286-293.
52. Wu, L., T. D. Martin, R. Vazeux, D. Unutmaz, and V. N. KewalRamani. 2002. Functional evaluation of DC-SIGN monoclonal antibodies reveals DCSIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission. J. Virol. 76:5905-5914.
53. Yang, X., Y. Chen, and D. Gabuzda. 1999. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J. Biol. Chem. 274:27981-27988.
54. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Y. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
55. Zack, J. A., A. M. Haislip, P. Krogstad, and I. S. Chen. 1992. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J. Virol. 66:1717-1725.
56. Zhang, L., C. Chung, B. S. Hu, T. He, Y. Guo, A. J. Kim, E. Skulsky, X. Jin, A. Hurley, B. Ramratnam, M. Markowitz, and D. D. Ho. 2000. Genetic characterization of rebounding HIV-1 after cessation of highly active anti-retroviral therapy. J. Clin. Investig. 106:839-845.